Mednax, Inc (NYSE:MD) Rating Reiterated by Jefferies Group LLC

Mednax, Inc (NYSE:MD)‘s stock had its “hold” rating reiterated by analysts at Jefferies Group LLC in a report released on Friday, November 3rd. They presently have a $44.00 target price on the stock. Jefferies Group LLC’s target price suggests a potential downside of 11.09% from the company’s previous close.

Several other equities analysts have also recently commented on the stock. KeyCorp set a $51.00 target price on shares of Mednax and gave the company a “buy” rating in a research note on Wednesday, November 1st. Robert W. Baird restated a “hold” rating and issued a $47.00 price objective on shares of Mednax in a research note on Sunday, September 3rd. Zacks Investment Research upgraded shares of Mednax from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. BMO Capital Markets initiated coverage on shares of Mednax in a report on Monday, October 16th. They issued a “market perform” rating and a $46.00 target price on the stock. Finally, Mizuho reaffirmed a “neutral” rating and issued a $48.00 target price (down previously from $62.00) on shares of Mednax in a report on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $54.50.

Shares of Mednax (MD) traded up $1.07 on Friday, reaching $49.49. 1,815,789 shares of the company were exchanged, compared to its average volume of 1,057,425. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.37 and a quick ratio of 1.37. The stock has a market capitalization of $4,541.34, a P/E ratio of 14.83, a PEG ratio of 1.56 and a beta of 0.32. Mednax has a 52-week low of $40.56 and a 52-week high of $72.13.

Mednax (NYSE:MD) last posted its earnings results on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.87. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The company had revenue of $868.95 million during the quarter, compared to the consensus estimate of $864.78 million. During the same period in the previous year, the firm posted $1.09 earnings per share. The company’s revenue for the quarter was up 4.9% compared to the same quarter last year. equities analysts predict that Mednax will post 3.1 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Mednax, Inc (NYSE:MD) Rating Reiterated by Jefferies Group LLC” was first published by BBNS and is owned by of BBNS. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/mednax-inc-md-earns-hold-rating-from-jefferies-group-llc/1756832.html.

In other news, insider John C. Pepia sold 3,000 shares of Mednax stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total value of $128,550.00. Following the sale, the insider now directly owns 35,569 shares in the company, valued at $1,524,131.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Cesar L. Alvarez sold 10,668 shares of the firm’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $42.59, for a total transaction of $454,350.12. Following the completion of the transaction, the director now directly owns 44,215 shares of the company’s stock, valued at $1,883,116.85. The disclosure for this sale can be found here. Company insiders own 2.40% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the business. OppenheimerFunds Inc. lifted its holdings in shares of Mednax by 14.5% during the first quarter. OppenheimerFunds Inc. now owns 11,379 shares of the company’s stock worth $789,000 after buying an additional 1,439 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Mednax by 0.5% during the first quarter. PNC Financial Services Group Inc. now owns 9,099 shares of the company’s stock worth $632,000 after buying an additional 47 shares in the last quarter. Morgan Stanley raised its stake in Mednax by 78.3% in the first quarter. Morgan Stanley now owns 361,509 shares of the company’s stock valued at $25,082,000 after purchasing an additional 158,720 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in Mednax by 7.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 279,799 shares of the company’s stock valued at $19,413,000 after purchasing an additional 19,592 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. raised its stake in Mednax by 1.3% in the first quarter. Nomura Asset Management Co. Ltd. now owns 11,300 shares of the company’s stock valued at $784,000 after purchasing an additional 140 shares in the last quarter. 96.44% of the stock is owned by hedge funds and other institutional investors.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Analyst Recommendations for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.